
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio is supported by a strengthening Jemperli royalty stream, with global net sales of $331M in 2Q26 and $644M in 1H26, up 26% and 34% year over year, respectively, while management still expects more than $390M of annualized royalties as early as 2029. The Canadian review acceptance for rectal cancer, alongside FDA priority review and Project Orbis, validates AZUR-1’s sustained complete responses for at least 12 months and expands the path for label growth beyond endometrial cancer. Additional upside comes from Quimilza’s FDA review with a December 12, 2026 PDUFA date and from multiple late-stage readouts that could further lift long-term sales and royalty visibility.
Bears say
AnaptysBio is a clinical-stage biotechnology company whose valuation depends heavily on speculative clinical and royalty-linked upside, making it vulnerable to setbacks across both its wholly owned programs and partnered assets. The key bearish factors are failed or inconclusive Jemperli trials, ongoing litigation with GSK, and regulatory risk around new indications and the submitted BLA for imsidolimab, any of which could weaken royalty growth, remove royalty upside optionality, or force additional capital needs. With added exposure to slower Jemperli uptake, stronger PD-1/PD-L1 competition, and financial results below expectations, the stock faces significant clinical, commercial, and contractual uncertainty.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About AnaptysBio (ANAB) Forecast
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares